To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
Double-blinded, Randomized, Active Control, Single Center-designed, Phase I Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of "HG-102" Compared to Botox® in Subjects With Moderate to Severe Glabellar Lines
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 05030
- Konkuk University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 19 and 65 at screening visit.
- Patients who voluntarily sign the informed consent.
- Patients who can comply with the study procedures and visit schedule.
Exclusion Criteria:
- Patients with infection, skin disorders, or scars at the glabellar region.
- Patients with facial palsy or the symptoms of blepharoptosis.
- Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception.
- Subjects who are not eligible for this study based on investigator's judgement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Botulinum toxin type A(Botox®)
Botulinum toxin type A(Botox®) 100 Unit
|
Single administration, Day 0, 20 units
Other Names:
|
|
EXPERIMENTAL: Botulinum toxin type A(HG-102)
Botulinum toxin type A(HG-102) 100 Unit
|
Single administration, Day 0, 20 units
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse event and adverse drug reaction incidence rates
Time Frame: Baseline to week 16
|
Baseline to week 16
|
|
Clinically-relevant changes in vital signs, physical exam, and laboratory testing assessed by medical personnel
Time Frame: 16 weeks (during the clinical trial)
|
16 weeks (during the clinical trial)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Responder rate of improvement in glabellar lines with Physician's rating line severity
Time Frame: Baseline to week 4, 8, 12, 16
|
Improvement rate of glabellar lines at maximum frown with Physician's rating line severity at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
Responder rate of improvement in glabellar lines with investigator's photo assessment
Time Frame: Baseline to week 4, 8, 12, 16
|
Improvement rate of glabellar lines at maximum frown with investigator's photo assessment at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
Responder rate of improvement in glabellar lines with Physician's rating line severity
Time Frame: Baseline to week 4, 8, 12, 16
|
Improvement rate of glabellar lines at rest with Physician's rating line severity at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
Responder rate of improvement in glabellar lines with investigator's photo assessment
Time Frame: Baseline to week 4, 8, 12, 16
|
Improvement rate of glabellar lines at rest with investigator's photo assessment at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
Changes in grade by physician's rating line severity for glabellar lines
Time Frame: Baseline to week 4, 8, 12, 16
|
Changes in grade(range from 0(None) to 3(Severe)) by physician's rating line severity for glabellar lines at each visit compared to baseline
|
Baseline to week 4, 8, 12, 16
|
|
Responder rate of improvement in glabellar lines with Subject's improvement assessment
Time Frame: Baseline to week 4, 8, 12, 16
|
Improvement rate of glabellar lines with Subject's improvement assessment at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
Subject's satisfaction rate
Time Frame: Baseline to week 4, 8, 12, 16
|
Subject's satisfaction rate of improvement in glabellar lines at 4, 8, 12, 16 weeks post injection
|
Baseline to week 4, 8, 12, 16
|
|
The severity of pain evaluated by the subject's Simple Descriptive Scale (SDS)
Time Frame: Baseline
|
The severity of pain evaluated by the subject's Simple Descriptive Scale (SDS) at immediately and about 30 minutes post injection (severity range is from 1(no pain) to 5(unbearable pain))
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HG-BOT102GL-PI-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.